INTRODUCTION

Background
 Clostridium difficile infection (CDI) is a growing global public health challenge, with dramatic increases in incidence, severity, mortality, and healthcare burden in recent years. 1, 2 The incidence of cases of recurrent CDI following initial treatment is also rising. 2  Clinical manifestations of C. difficile infection range from diarrhoea of varying degrees of severity to colitis, systemic toxic shock, and even death.
3
Participants
 Patients with CDAD meeting study eligibility criteria (Table 1) were recruited at 5 participating study sites in the US.
 All patients provided written informed consent.
 Nurses from the 5 participating sites who treated CDAD patients on a regular basis were recruited to participate in supplemental interviews in Phase 1.
Phase 1: Concept elicitation interviews
 Patients' spontaneously reported experiences with CDAD symptoms were gathered from patient interviews as well as supplemental interviews with nurses, who were asked about symptoms reported by patients.
 Once concept saturation was reached, the draft PRO, named the CDAD-DaySyms™, was developed with input from the panel of clinical experts.
 The draft PRO was reviewed by a translation expert to assess the ease of future translation to other languages and to determine lexibility (grade level and readability).
Phase 2: Cognitive interviews
 Patients with CDAD were interviewed by telephone in 2 iterative rounds, and asked to complete the PRO.
 Interviewers used a semi-structured interview guide to obtain feedback on:
-Relevance, comprehensibility, acceptability, and compre-hensiveness of the questionnaire items -Interpretability and appropriateness of the instructions, response options, and recall period
RESULTS
Participant sample
 A total of 34 patients and 6 nurses were recruited across both study phases.
 Patient characteristics are shown in Table 2 . Recruitment targets were generally met, though there were fewer patients than anticipated with first-recurrence and hospital-acquired CDAD.  Symptoms of C. difficile-associated diarrhoea (CDAD) are important because they impair patient functioning and quality of life. 4  Since the patient voice in the drug approval process is becoming more prominent, 5 clinical studies of new agents for CDAD should evaluate symptoms in addition to objective clinical assessments; however, no patientreported outcome (PRO) questionnaire measuring symptoms is currently available.
Kleinman
METHODS
Study design
 A cross-sectional, qualitative research study was undertaken consisting of 2 main phases ( Figure 1  Severity-based response options were chosen, using a 5-point Likert type rating scale with options of none, mild, moderate, severe and very severe.
 A 24-hour recall period was chosen because symptoms are variable day to day, may progress quickly, and may begin to respond to therapy within 1-2 days.
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Phase 2
 Patients reported that the symptoms in the PRO were relevant to their everyday experience with the disease.
 The formatting and phrasing of the PRO including the instructions, items and response options were clear and easy to understand, and patients were able to use the questionnaire as intended. 
